Back to top

UBS Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)

In a report released on July 1, from UBS maintained a Buy rating on BeOne Medicines Ltd, with a price target of HK$273.60. BeOne Medicines Ltd has ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BeOne Medicines Ltd. - Sponsored ADR (ONC)